Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$45.98 USD
+0.81 (1.79%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $45.85 -0.13 (-0.28%) 8:14 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.98 USD
+0.81 (1.79%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $45.85 -0.13 (-0.28%) 8:14 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Strength Seen in Sage Therapeutics, Inc. (SAGE): Can Its 11.8% Jump Turn into More Strength?
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.23% and 15.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 16.87% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -16.13% and -88.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Revolution Medicines, Inc. (RVMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.09% and -19.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Revolution Medicines, Inc. (RVMD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -1.92% and 0.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in Session
by Zacks Equity Research
Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Revolution Medicines (RVMD) Catches Eye: Stock Jumps 10.2%
by Zacks Equity Research
Revolution Medicines (RVMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.